Oppenheimer & Co. Inc. Buys Shares of 7,675 Uniqure NV (QURE)
Oppenheimer & Co. Inc. bought a new position in Uniqure NV (NASDAQ:QURE) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 7,675 shares of the biotechnology company’s stock, valued at approximately $279,000.
Several other hedge funds also recently bought and sold shares of QURE. California Public Employees Retirement System purchased a new position in shares of Uniqure during the first quarter worth about $332,000. Jane Street Group LLC purchased a new position in shares of Uniqure during the first quarter worth about $224,000. Ladenburg Thalmann Financial Services Inc. grew its holdings in shares of Uniqure by 276.5% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,400 shares of the biotechnology company’s stock worth $150,000 after buying an additional 4,700 shares during the last quarter. Atria Investments LLC purchased a new position in shares of Uniqure during the second quarter worth about $247,000. Finally, Fred Alger Management Inc. purchased a new position in shares of Uniqure during the second quarter worth about $983,000. 59.10% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:QURE opened at $25.72 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.56 and a quick ratio of 8.36. The stock has a market capitalization of $1.04 billion, a P/E ratio of -8.75 and a beta of 0.78. Uniqure NV has a 52 week low of $13.71 and a 52 week high of $43.23.
A number of equities analysts recently issued reports on the company. BidaskClub lowered Uniqure from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. Cantor Fitzgerald set a $58.00 price target on Uniqure and gave the stock a “buy” rating in a report on Saturday, August 11th. Zacks Investment Research lowered Uniqure from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 25th. HC Wainwright set a $48.00 price target on Uniqure and gave the stock a “buy” rating in a report on Thursday, October 11th. Finally, Chardan Capital reissued a “buy” rating and set a $50.00 price target on shares of Uniqure in a report on Thursday, October 18th. Three equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $49.67.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
See Also: Cost of Capital Explained
Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Uniqure NV (NASDAQ:QURE).
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.